Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Peripheral Nerve Sheath Tumors (MPNST): early-phase trial registry
1 of 2 indexed Malignant Peripheral Nerve Sheath Tumors (MPNST) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Malignant Peripheral Nerve Sheath Tumors (MPNST): 2 US clinical trials tracked, 1 recruiting.
Malignant Peripheral Nerve Sheath Tumors (MPNST) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Ascentage Pharma Group, running 1 of these trials.
Enrollment posture brief
Registry condition malignant-peripheral-nerve-sheath-tumors-mpnst
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Malignant Peripheral Nerve Sheath Tumors (MPNST) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Peripheral Nerve Sheath Tumors (MPNST) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Peripheral Nerve Sheath Tumors (MPNST) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Memorial Sloan Kettering Cancer Center
NCT04872543
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group
NCT03611868
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Peripheral Nerve Sheath Tumors (MPNST) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Peripheral Nerve Sheath Tumors (MPNST) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Peripheral Nerve Sheath Tumors (MPNST) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Malignant Peripheral Nerve Sheath Tumors (MPNST) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ascentage Pharma Group sponsors the most Malignant Peripheral Nerve Sheath Tumors (MPNST) trials on record, review their full trial history before evaluating a specific study. See Ascentage Pharma Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Peripheral Nerve Sheath Tumors (MPNST) condition card totals 2 registered trials; most-linked intervention Phase 1b: APG-115+pembrolizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.